Abstract
Pharmacogenomics is an evolving research discipline within ophthalmology. An early application appears to involve open-angle glaucoma, a common cause of worldwide preventable blindness. Primary open-angle glaucoma is primarily treated with medications, and the two most common classes of drugs are β-adrenergic receptor antagonists and prostaglandin analogs. One small clinical trial has documented a pharmacogenomic relationship between polymorphisms in the β1-adrenergic receptor with the selective β1-antagonist betaxolol. A second small clinical trial has documented a pharmacogenomic relationship between polymorphisms in the prostaglandin F2α receptor and the prostaglandin analog latanoprost. A small pilot study has not found any significant pharmacogenomic relationship between polymorphisms in the glucocorticoid receptor and intraocular pressure elevation following treatment with intravitreal triamcinolone acetonide. Pharmacogenomics may explain some of the well-documented variability in response to common glaucoma medications.
Current Pharmacogenomics and Personalized Medicine
Title: Pharmacogenomics of Open-Angle Glaucoma
Volume: 6 Issue: 2
Author(s): Stephen G. Schwartz, Juan A. Ayala-Haedo, Krishna S. Kishor and M. Elizabeth Fini
Affiliation:
Abstract: Pharmacogenomics is an evolving research discipline within ophthalmology. An early application appears to involve open-angle glaucoma, a common cause of worldwide preventable blindness. Primary open-angle glaucoma is primarily treated with medications, and the two most common classes of drugs are β-adrenergic receptor antagonists and prostaglandin analogs. One small clinical trial has documented a pharmacogenomic relationship between polymorphisms in the β1-adrenergic receptor with the selective β1-antagonist betaxolol. A second small clinical trial has documented a pharmacogenomic relationship between polymorphisms in the prostaglandin F2α receptor and the prostaglandin analog latanoprost. A small pilot study has not found any significant pharmacogenomic relationship between polymorphisms in the glucocorticoid receptor and intraocular pressure elevation following treatment with intravitreal triamcinolone acetonide. Pharmacogenomics may explain some of the well-documented variability in response to common glaucoma medications.
Export Options
About this article
Cite this article as:
Schwartz G. Stephen, Ayala-Haedo A. Juan, Kishor S. Krishna and Fini Elizabeth M., Pharmacogenomics of Open-Angle Glaucoma, Current Pharmacogenomics and Personalized Medicine 2008; 6 (2) . https://dx.doi.org/10.2174/1875692110806020121
DOI https://dx.doi.org/10.2174/1875692110806020121 |
Print ISSN 1875-6921 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6913 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Intravitreal Triamcinolone in Diabetic Retinopathy
Current Diabetes Reviews Subthreshold Laser Therapy for Diabetic Macular Edema: Metabolic and Safety Issues
Current Medicinal Chemistry Targeted Drug Delivery and Imaging Using Mobile Milli/Microrobots: A Promising Future Towards Theranostic Pharmaceutical Design
Current Pharmaceutical Design Involvement of Orbital Structures in Rheumatic Disease
Current Rheumatology Reviews Targeting Plasminogen Activator Inhibitor-1: Role in Cell Signaling and the Biology of Domain-Specific Knock-in Mice
Current Drug Targets Intravitreal Bevacizumab (Avastin®) for Diabetic Retinopathy at 24-months: The 2008 Juan Verdaguer-Planas Lecture
Current Diabetes Reviews The Valsalva Maneuver and Alzheimers Disease: Is there a link?
Current Alzheimer Research Platelet Resistance to the Anti-Aggregating Agents in the Insulin Resistant States
Current Diabetes Reviews Drug Delivery to the Posterior Segment of the Eye: Challenges and Opportunities
Drug Delivery Letters Effects of Insulin on the Vasculature
Current Vascular Pharmacology Blood Platelet Reactivity and its Pharmacological Modulation in (People with) Diabetes Mellitus
Current Pharmaceutical Design The Role of Venous Abnormalities in Neurological Disease
Reviews on Recent Clinical Trials Therapeutic Potential of Erythropoietin in Retinal and Optic Nerve Diseases
CNS & Neurological Disorders - Drug Targets Targeting Calcium Channels to Block Tumor Vascularization
Recent Patents on Anti-Cancer Drug Discovery VEGF Mediates ApoE4-Induced Neovascularization and Synaptic Pathology in the Choroid and Retina
Current Alzheimer Research Renal Injury Following Intravitreal Anti-VEGF Administration in Diabetic Patients with Proliferative Diabetic Retinopathy and Chronic Kidney Disease - A Possible Side Effect?
Current Drug Safety The Hellp Syndrome: A Review
Current Women`s Health Reviews Cerebral Vascular Aging: Extending the Concept of Pulse Wave Encephalopathy Through Capillaries to the Cerebral Veins
Current Aging Science Leukocytes in Diabetic Retinopathy
Current Diabetes Reviews The Involvement of Blood Coagulation Factor XIII in Fibrinolysis and Thrombosis
Cardiovascular & Hematological Agents in Medicinal Chemistry